D.A. Davidson & CO. Sells 1,102 Shares of Sanofi (SNY)
D.A. Davidson & CO. cut its stake in Sanofi (NYSE:SNY) by 17.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,359 shares of the company’s stock after selling 1,102 shares during the quarter. D.A. Davidson & CO.’s holdings in Sanofi were worth $256,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Harbour Capital Advisors LLC acquired a new position in shares of Sanofi during the first quarter worth about $113,000. Parallel Advisors LLC boosted its position in shares of Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after buying an additional 875 shares during the period. Eagle Ridge Investment Management purchased a new stake in shares of Sanofi in the second quarter worth about $160,000. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after buying an additional 3,713 shares during the period. Finally, Bronfman E.L. Rothschild L.P. boosted its position in shares of Sanofi by 142.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after buying an additional 2,098 shares during the period. 9.33% of the stock is currently owned by institutional investors.
In related news, major shareholder Sanofi purchased 60,595 shares of the stock in a transaction on Wednesday, August 23rd. The shares were bought at an average price of $478.98 per share, for a total transaction of $29,023,793.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.00% of the stock is owned by corporate insiders.
A number of equities research analysts have recently issued reports on the company. Argus reiterated a “buy” rating and issued a $55.00 target price on shares of Sanofi in a research note on Friday, September 1st. BidaskClub upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. HSBC Holdings plc raised Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Cowen and Company reissued a “market perform” rating and set a $52.00 price target (up from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $54.00.
Shares of Sanofi (NYSE:SNY) opened at 49.80 on Wednesday. The stock has a market capitalization of $125.07 billion, a price-to-earnings ratio of 11.56 and a beta of 0.87. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.65. The stock’s 50 day moving average price is $48.98 and its 200-day moving average price is $47.88.
Sanofi (NYSE:SNY) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. The firm’s revenue was down 2.3% compared to the same quarter last year. Equities analysts forecast that Sanofi will post $3.33 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “D.A. Davidson & CO. Sells 1,102 Shares of Sanofi (SNY)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/04/d-a-davidson-co-sells-1102-shares-of-sanofi-sny.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.